SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-304290
Filing Date
2022-12-14
Accepted
2022-12-14 06:06:04
Documents
14
Period of Report
2022-12-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d313448d8k.htm   iXBRL 8-K 25980
2 EX-99.1 d313448dex991.htm EX-99.1 7980
6 GRAPHIC g313448g1214042552244.jpg GRAPHIC 4187
  Complete submission text file 0001193125-22-304290.txt   164447

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20221213.xsd EX-101.SCH 2891
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20221213_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20221213_pre.xml EX-101.PRE 11289
8 EXTRACTED XBRL INSTANCE DOCUMENT d313448d8k_htm.xml XML 3366
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 221461095
SIC: 2834 Pharmaceutical Preparations